11:00 AM EDT, 10/22/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target price by $50 to $340 on a forward P/E of 29.0x our 2026 earnings estimate, a premium to the three-year historical average of 23.2x given strong margins and fewer concerns surrounding competitive threats. We reduce our 2025 EPS estimate to $11.12 from $11.26 and increase 2026's to $11.72 from $11.68. CME represents an exceptional hedge against market uncertainty, as the company benefits disproportionately during periods of financial stress. Given that volatility consensus expectations have declined substantially since April, we believe the current environment presents an attractive entry point for CME shares. The risk-reward profile has shifted meaningfully in investors' favor. Our upgraded stance reflects improved valuation metrics. After downgrading shares in April, when CME traded at a 20% premium to the S&P 500 on a forward P/E basis, the current levels appear far more compelling with shares now trading at just a 1% premium to the broader market.